Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Senti Biosciences (SNTI) Change in Acquisitions & Divestments (2023)

Senti Biosciences has reported Change in Acquisitions & Divestments over the past 1 years, most recently at $23.0 million for Q3 2023.

For Q3 2023, Change in Acquisitions & Divestments changed N/A year-over-year to $23.0 million; the TTM value through Jun 2024 reached $23.0 million, down 37.84%, while the annual FY2023 figure was $60.0 million, N/A changed from the prior year.
Change in Acquisitions & Divestments for Q3 2023 was $23.0 million at Senti Biosciences, up from $22.0 million in the prior quarter.
Over five years, Change in Acquisitions & Divestments peaked at $23.0 million in Q3 2023 and troughed at $15.0 million in Q1 2023.